For years, patients with C3G and IC-MPGN had few options to stop the progression toward kidney failure. Now a new class of FDA-approved C3 inhibitors that targets the root of the complement system can ...

The article, titled "Emerging roles of immune cell-derived neurotransmitters in immunity and disease," published on March 17, ...